Journey Medical Soars 12.86% Ahead of Conference

On August 19, 2025, Journey Medical's stock surged by 12.86% in pre-market trading, reflecting a significant boost in investor confidence and market sentiment.

Journey Medical Corporation, a commercial-stage pharmaceutical company, is set to present at the Emerging Growth Conference on August 20, 2025. Claude Maraoui, the company's Co-Founder, President, and CEO, will deliver a corporate overview, highlighting the company's focus on dermatological treatments and its efficient sales and marketing model.

The presentation is expected to provide insights into Journey Medical's innovative strategies and recent developments in the dermatological sector. The company currently markets eight branded FDA-approved prescription drugs, addressing common skin conditions with a team of industry experts.

This presentation is part of Journey Medical's ongoing efforts to engage with investors and stakeholders, showcasing its commitment to advancing dermatological treatments and maintaining transparency in its operations.